ArticleNature2025
Taurine from tumour niche drives glycolysis to promote leukaemogenesis.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Salivary metabolic profile in patients with oral squamous cell carcinoma and potentially malignant disorders.Clinical oral investigations · 2026Article
- CDO1 as a prognostic biomarker and therapeutic target in gastric cancer: Mechanistic insights into the PI3K/AKT-THBS1 axis and epigenetic reactivation by decitabine.Clinical and translational medicine · 2026Article
- Compartmental pH regulation in cancer and antitumor immunity: therapeutic opportunities and challenges.Apoptosis : an international journal on programmed cell death · 2026Review
- LC-QQQ serum metabolomics reveals disease-specific metabolic signatures and diagnostic metabolite panels distinguishing polycythaemia vera from secondary polycythaemia.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia.HemaSphere · 2026Article
- Amino Acids as Targets for Immunotherapy against Solid Tumors.Cell biochemistry and biophysics · 2026Review
- Metabolic Crosstalk Between Host and Tumor as a Circuit of Resilience in Cancer Therapy.Cells · 2026Review
- Solute carrier transporters as metabolic gatekeepers in tumor-microenvironment crosstalk.Acta pharmacologica Sinica · 2026Review
- Clinico-Metabolic Profiling Unraveled Key Metabolic Alterations Underlying the Pathophysiology of Chronic Myeloid Leukemia.ACS omega · 2026Article
- The fluoroquinoline compound exerts anti-erythroleukemic effects by dual-targeting GLUT1 and the PI3K/AKT signaling pathway.Scientific reports · 2026Article
- Intrinsic and niche-dependent metabolic regulation of haematopoietic stem cells and implications for leukaemogenesis.Nature cell biology · 2026Review
- SLC6A6 imports taurine into mitochondria to sustain mitochondrial translation and tumour growth.Nature metabolism · 2026Article
- Taurine is a natural suppressor of urea cycle via targeting ASL.Cell death discovery · 2026Article
- Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.Experimental hematology & oncology · 2026Article
- Article
- Taurine transporter SLC6A6 expression promotes mesenchymal stromal cell function.Cell death & disease · 2026Article
- Modulation of Aerobic Glycolysis Genes During the Progression of Retinitis Pigmentosa.Investigative ophthalmology & visual science · 2026Article
- Defining the role of natural killer cells in acute myeloid leukemia through the lens of single-cell omics.Frontiers in immunology · 2026Review
- Taurine Facilitates the Formation of Hepatocellular Carcinoma via the Bile Acid Pathway.Metabolites · 2025Article
- Fast multimodal imaging combined with machine learning identifying taurine as a potential marker for breast cancer margin assessment.NPJ digital medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Sonali Sharma *Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA.
Benjamin J Rodems *Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA.
Cameron D Baker *Genomics Research Center, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-3792-4317
Christina M Kaszuba *Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Edgardo I FrancoWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Bradley R SmithDepartment of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, USA.
Takashi ItoDepartment of Bioscience and Technology, Graduate School of Bioscience and Technology, Fukui Prefectural University, Fukui, Japan.
Kyle SwovickMass Spectrometry Resource Laboratory, University of Rochester, Rochester, NY, USA.ORCID 0000-0003-1161-7957
Kevin WelleMass Spectrometry Resource Laboratory, University of Rochester, Rochester, NY, USA.
Yi ZhangDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Philip RockDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Francisco A ChavesWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-2818-2526
Sina GhaemmaghamiMass Spectrometry Resource Laboratory, University of Rochester, Rochester, NY, USA.
Laura M CalviWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0001-6969-239X
Archan GangulyDepartment of Neuroscience, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-0351-9284
W Richard BurackDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-5584-584X
Michael W BeckerWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Jane L LiesveldWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Paul S BrookesDepartment of Anesthesiology, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-8639-8413
Joshua C MungerWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0001-5379-9440
Craig T JordanDivision of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-0869-3465
John M AshtonDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0001-9875-5994
Jeevisha BajajDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA. Jeevisha_Bajaj@URMC.Rochester.edu.ORCID 0000-0002-8411-6056
Funding
National Metabolomics Data Repository - nextgen Metabolomics WorkbenchU2CDK119886 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2018 to 2021
$12.7MRochester Resource-Based Center for Bone, Muscle and Orthopaedic Research (ROCSTARR) (Overall Application)P30AR069655 · NIAMS · UNIVERSITY OF ROCHESTER · PI Edward M. Schwarz · 2016 to 2026
$7.8MUniversity of Rochester Wilmot Cancer Institute Support GrantP30CA272302 · NCI · UNIVERSITY OF ROCHESTER · PI JONATHAN W FRIEDBERG · 2025 to 2026
$6.4MTherapeutic Targeting of Human AML Stem CellsR35CA242376 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2020 to 2026
$5.6MBiomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2020 to 2024
$3.2MMechanisms of marrow microenvironmental aging and their impact of progression of clonal hematopoiesisR01AG079556 · NIA · UNIVERSITY OF ROCHESTER · PI Laura M Calvi, JANE L. LIESVELD · 2022 to 2026
$2.7MEfferocytosis by Bone Marrow Stromal Cells and Bone AgingR01AG076786 · NIA · UNIVERSITY OF ROCHESTER · PI Laura M Calvi, Roman Eliseev · 2022 to 2026
$2.4MMetabolic modulation by the HCMV UL38 geneR01AI150698 · NIAID · UNIVERSITY OF ROCHESTER · PI JOSHUA C MUNGER · 2020 to 2026
$2.4MTargeting Microenvironmental Signals in Myeloid MalignanciesR01CA266617 · NCI · UNIVERSITY OF ROCHESTER · PI Jeevisha Bajaj · 2022 to 2026
$2.4MMetabolism and HCMV: determinants of the antiviral stateR01AI181865 · NIAID · UNIVERSITY OF ROCHESTER · PI JOSHUA C MUNGER · 2024 to 2026
$1.8MTraining in Musculoskeletal Science: Comprehensive Training in Pain StudiesT32AR076950 · NIAMS · UNIVERSITY OF ROCHESTER · PI Hani A Awad, Laura M Calvi · 2020 to 2026
$1.7MDefining and Manipulating the Endothelial Niche in Myelodysplastic SyndromesR01DK133131 · NIDDK · UNIVERSITY OF ROCHESTER · PI BAJAJ, JEEVISHA · 2022 to 2024
$684kNCI NIH HHS P30 CA272302NCI NIH HHS R01 CA266617NCI NIH HHS R35 CA242376NIAID NIH HHS R01 AI150698NIAID NIH HHS R01 AI181865NIAMS NIH HHS P30 AR069655NIAMS NIH HHS T32 AR076950NIA NIH HHS R01 AG076786NIA NIH HHS R01 AG079556NIDDK NIH HHS R01 DK133131NIDDK NIH HHS U2C DK119886NIH HHS OT2 OD030544
Abstract
Signals from the microenvironment are known to be critical for development, stem cell self-renewal and oncogenic progression. Although some niche-driven signals that promote cancer progression have been identified
Indexed as
CarcinogenesisGlycolysisLeukemia, Myeloid, AcuteTaurineTumor MicroenvironmentAnimalsDisease ProgressionFemaleHumansMaleMembrane GlycoproteinsMembrane Transport ProteinsMiceNeoplastic Stem CellsSingle-Cell AnalysisTaurine TransportersMembrane GlycoproteinsMembrane Transport ProteinsTaurineTaurine TransportersTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.